Wednesday, September 24, 2014 at 12:00 p.m. ET

Thus far, 2014 has seen a number of interesting cases involving pharmaceutical and medical device companies. Taken together, the outcomes of these cases indicate the current direction of drug and device product liability litigation and how certain legal issues in the industry may be handled in the future.

Join Drug and Device Law blog contributors/Reed Smith attorneys Jim Beck (Bexis), Steve McConnell, and Steven Boranian for a one-hour teleseminar discussing these litigation trends, their potential effects on the pharmaceutical and medical device industry, and how companies should prepare themselves going forward. Among the trends to be discussed are the overall impact of generic drug-related preemption on the litigation landscape; continued battles over innovator liability; learned intermediary rule developments; and innovative claims, such as those involving sales representative conduct, alleged FDCA violations, pharmaco-vigilance/duty to report, and duty to train. This hour-long program will be relevant to in-house counsel, business personnel, and all other interested parties.

Please click here to listen to a recording of the teleseminar.